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The etiology of hypertriglyceridemia (HTG) and acute pancreatitis (AP) is complex.
Herein, we dissected the underlying etiology in a patient with HTG and AP. The patient
had a 20-year history of heavy alcohol consumption and an 8-year history of mild
HTG. He was hospitalized for alcohol-triggered AP, with a plasma triglyceride (TG)
level up to 21.4 mmol/L. A temporary rise in post-heparin LPL concentration (1.5–
2.5 times of controls) was noted during the early days of AP whilst LPL activity was
consistently low (50∼70% of controls). His TG level rapidly decreased to normal in
response to treatment, and remained normal to borderline high during a ∼3-year
follow-up period during which he had abstained completely from alcohol. Sequencing
of the five primary HTG genes (i.e., LPL, APOC2, APOA5, GPIHBP1 and LMF1)
identified two heterozygous variants. One was the common APOA5 c.553G > T
(p.Gly185Cys) variant, which has been previously associated with altered TG levels
as well as HTG-induced acute pancreatitis (HTG-AP). The other was a rare variant
in the LPL gene, c.756T > G (p.Ile252Met), which was predicted to be likely
pathogenic and found experimentally to cause a 40% loss of LPL activity without
affecting either protein synthesis or secretion. We provide evidence that both a gene-
gene interaction (between the common APOA5 variant and the rare LPL variant)
and a gene-environment interaction (between alcohol and digenic inheritance) might
have contributed to the development of mild HTG and alcohol-triggered AP in the
patient, thereby improving our understanding of the complex etiology of HTG and
HTG-AP.
Keywords: acute pancreatitis, alcohol-induced hypertriglyceridemia, LPL gene, APOA5 gene, gene-environment
interaction
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INTRODUCTION
Acute pancreatitis (AP) is a common critical disease, has poor
outcomes and a high mortality rate, and requires complex clinical
management (Hazra and Gulliford, 2014; Lee and Papachristou,
2019). The etiology of AP is diverse (AGA, 2007; IAP/APA,
2013). In Western countries, gallstones and alcohol consumption
represent the most common causes (Sekimoto et al., 2006; Yadav
and Lowenfels, 2013) whereas in China, hypertriglyceridemia
(HTG) rather than alcohol consumption is the second leading
cause (Yin et al., 2015; Jin et al., 2019). Hypertriglyceridemia-
induced acute pancreatitis (HTG-AP) has been defined as
pancreatitis with a triglyceride (TG) level of up to 1000 mg/dL
(11.3 mmol/L) alone, or 500 mg/dL (5.65 mmol/L) accompanied
by lipemic or lactescent (milky in appearance) blood, after
excluding other etiologies (Zafrir et al., 2018). By comparison
with biliary acute pancreatitis, HTG-AP occurs earlier, is more
severe, has a higher recurrence rate, and affects more males than
females (Yin et al., 2015; Li et al., 2018; Jin et al., 2019).
HTG can be broadly divided into primary and secondary
categories in terms of etiology (Yuan et al., 2007; Rygiel, 2018).
Secondary HTG is primarily related to lifestyle factors such as
heavy alcohol consumption and smoking, physiological factors
such as pregnancy, or comorbid pathological conditions
such as obesity, diabetes mellitus, hypothyroidism, and
renal dysfunction (Black and Sprecher, 1993; Merkel et al.,
2002). By contrast, primary HTG has been found to be
mainly due to genetic defects in five lipid metabolism-related
genes (Nawawi et al., 2020) namely LPL (lipoprotein lipase,
OMIM #609708), LMF1 (lipase maturation factor 1, OMIM
#611761), GPIHBP1 (glycosylphosphatidylinositol-anchored
high density lipoprotein-binding protein 1, OMIM #612757),
APOA5 (apolipoprotein A-V, OMIM #606368), and APOC2
(apolipoprotein C-II, OMIM #608083). LPL is the key enzyme
catabolizing triglyceride (Olivecrona, 2016). LMF1 functions in
the maturation of LPL (Peterfy et al., 2007). GPIHBP1 mediates
the transmembrane transport and binding of LPL (Beigneux
et al., 2007). APOA5 and APOC2 act as basic activators of LPL
activity (Breckenridge et al., 1978; Pennacchio et al., 2001).
The abovementioned dichotomous classification of HTG
provides a useful framework for understanding the etiology
of HTG. However, in most cases, the etiology of HTG is
complex, and often involves primary-primary (i.e., gene-gene)
and primary-secondary (i.e., gene-environment) interactions
(Wang et al., 2008; Hegele et al., 2014; Cole et al., 2015; Serveaux
Dancer et al., 2018; Chen et al., 2019; Dron et al., 2019; Pu et al.,
2020). Herein, we describe the clinical, genetic and functional
analysis of a patient with alcohol-triggered HTG-AP, which




This study was approved by the Ethics Committee of Jinling
Hospital. Informed consent for publication was obtained from
all participants.
Patient
The male Chinese patient experienced sudden upper abdominal
pain after consuming ∼150 g alcohol on October 29, 2017. He
was initially admitted to a local hospital: physical examination
revealed epigastric tenderness, without Gray Turner’s or Cullen’s
sign; amylase increased from 305 U/L to 1,294 U/L over one
night; a computed tomography (CT) scan indicated AP. He
was transferred to our severe acute pancreatitis treatment center
in Jinling Hospital on October 31, 2017. Diagnosis of AP and
classification of the disease in terms of clinical severity were
made in accordance with the modified Atlanta classification
(Banks et al., 2013).
Analysis of Plasma Lipid Profiles
Fasting blood samples were collected for this analysis. Plasma
lipid profiles including TG, total cholesterol (TC), high-density
lipoprotein cholesterol (HDL-C) and low-density lipoprotein
cholesterol (LDL-C), as well as plasma glucose were measured
enzymatically on an automatic analyzer (Hitachi High-Tech,
7600–120, Japan).
Analysis of LPL Mass and Activity in
Post-heparin Plasma
Blood samples were collected after overnight fasting and 10 min
after intravenous heparin injection (60 IU/kg body weight).
LPL mass was determined using a human LPL Elisa kit (TSZ
Biological Trade Co., Ltd., San Francisco, CA, United States) in
accordance with the manufacturer’s instructions. To measure LPL
activity, plasma total lipase activity and hepatic lipase activity
were first determined by a LPL-mediated lipolysis reaction; this
was performed by means of a free fatty acid (FFA) release
assay kit [Wako kit# NEFA-HR(2), Japan], using TG-rich plasma
from GPIHBP1-deficient (GPIHBP1−/−) mice as the lipolytic
substrate (Li et al., 2020; Shi et al., 2020). It should be noted that,
for the hepatic lipase activity assay, the sample was pretreated
with 1 M NaCl and incubated for 60 min at 4◦C in order to
inactivate LPL. Subtraction of the hepatic lipase activity from the
total lipase activity then yielded a measure of the plasma LPL
activity. All assays were performed in five replicates. Eight healthy
volunteers from our center (four males and four females with a
mean age of 28 years) were used as controls.
Sanger Sequencing
Genomic DNA was extracted from a blood sample using
the TIANamp Blood DNA kit (TIANGEN Biotech, Beijing,
China) according to the manufacturer’s instructions. All coding
and proximal intronic regions of the LPL, APOC2, APOA5,
GPIHBP1, and LMF1 genes were analyzed by Sanger sequencing
as previously described (Chen et al., 2019; Pu et al., 2020). All
primer sequences are available upon email request.
Reference Sequences, Variant
Nomenclature, Public Databases, and
Pathogenicity Prediction for Missense
Variants
NM_000237, NM_000483, NM_001371904, NM_178172, and
NM_022773 were used as the mRNA reference sequences for the
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LPL, APOC2, APOA5, GPIHBP1, and LMF1 genes, respectively.
Variant nomenclature followed the Human Genome Variation
Society (HGVS) recommendations (den Dunnen et al., 2016).
Variant population allele frequencies were in accordance with
the Genome Aggregation Database (gnomAD)1 (Karczewski
et al., 2020). The Human Gene Mutation Database (HGMD)2
(Stenson et al., 2020), ClinVar3, the LPL locus-specific mutation
database4 and PubMed5 were used to establish whether or not
a given variant had been previously described. LPL amino
acid sequences from diverse vertebrate species were taken
from https://www.ncbi.nlm.nih.gov/home/proteins/to evaluate
the evolutionary conservation status of the p.Ile252 position. As
previously described (Guéguen et al., 2020), we used the PP3
rule established by VarSome (Kopanos et al., 2019) to predict
the pathogenicity of missense variants; the PP3 verdict was
based upon computational evidence derived from 13 in silico
algorithms (i.e., BayesDel_addAF, DANN, DEOGEN2, EIGEN,
FATHMM-MKL, M-CAP, MutationAssessor, MutationTaster,
MVP, PrimateAI, REVEL, and SIFT).
Plasmid Construction, Cell Culture, and
Transfection
The wild-type LPL cDNA expression vector has been previously
described (Li et al., 2020; Shi et al., 2020) and was used here
to generate the mutant [c.756T > G (p.Ile252Met)] expression
vector by site-directed mutagenesis. The mutated site was
verified by Sanger sequencing. Human embryonic kidney 293T
(HEK293T) cells (ATCC, CRL-3216) were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM, Lonza, C11995500BT) with
10% Fetal Bovine serum (FBS) and 1% penicillin-streptomycin
at 37◦C with 5% CO2. Transfections were performed using
Lipofectamine 3000 (Thermo, L3000015) in 6-well plates,
essentially as previously described (Yu et al., 2006; Han et al.,
2020). It should, however, be noted that in addition to the
wild-type expression vector, mutant expression vector and
empty vector transfection groups, a new group mimicking the
heterozygous state of the variant was included here. More
specifically, whereas the former three groups each used 3 µg
of the respective plasmid for transfection, the new group used
a mix of 1.5 µg wild-type plasmid and 1.5 µg mutant plasmid
for transfection. Moreover, whereas the transfection time (i.e.,
from addition of the plasmid into the culture media to the
change to fresh media) was invariably maintained for 6 h,
downstream treatments were different in accordance with the
subsequent Western blot analysis. Thus, for analysis of LPL
expressed in the transfected cells without heparin treatment,
the cells were cultured for 48 h with the fresh media before
cell lysate preparation. For analysis of LPL expressed in the
transfected cells and secreted into the media, the fresh medium
was further changed to a 500 µL heparin-DMEM mixture (the






20 units/mL) per well; the cells were cultured for an additional
30 min. Three independent transfections were performed for
each experiment.
Western Blot
Transfected cell medium was centrifuged at 12,000 r/min for
5 min to remove cells and cell debris and stored at –80◦C for later
analysis. Transfected cells were treated with 80 µL RIPA Lysis
Buffer (Beyotime, P0013B, China) and 8 µL protease inhibitor
(PI, Roche, 4693116001) and centrifuged at 12,000 r/min for
5 min; the supernatant was stored at −80◦C for subsequent
analysis. Protein concentration was determined by BCA kit.
30 µg cell lysates or 200 µL cell media were mixed with
SDS-PAGE Protein Loading Buffer (reducing) and incubated at
95◦C for 10 min. It should be noted that the cell media were
firstly concentrated in the upper layer of the polyacrylamide gel
(concentration of 12%) by repeated sample loading (40 µL × 5
times; each time run at 90 V for 15 min). Proteins were
separated by SDS-PAGE (10% acrylamide gel, 130 V, 90 min),
transferred onto a nitrocellulose membrane (220 mA, 120 min),
and then blocked with 5% BSA (room temperature, 60 min).
After washing with 0.2% Tris-Buffered Saline with Tween 20
(TBST), membranes were incubated overnight with mouse
anti-LPL antibody (Santa, sc-73646; 1:200 dilution) at 4◦C.
After washing with 0.2% TBST, membranes were incubated for
1 h with goat anti-mouse (Abcam, ab6728; 1:2000 dilution)
IgG H&L (HRP) antibody, and again washed three times.
After 5 min incubation with chemiluminescent HRP substrate
(Thermo Fisher Scientific), bands were visualized and analyzed
by the Chemidoc XRS System, Image Lab Software (Clinx
Science Instruments, Shanghai, China). The protein bands were
quantified by densitometry and normalized to GAPDH (Santa,
sc-69778; 1:2000 dilution).
LPL Activity Analysis in Transfected Cell
Medium and Lysates
This was performed in the same way as for the analysis of LPL
activity in post-heparin plasma, but without the treatment with
1M NaCl, as there was no hepatic lipase activity in the cell
medium or lysates. Each assay was performed in five replicates.
Statistical Analysis
Results from Western blot and LPL activity analysis in transfected
cell medium and lysates are shown as mean ± standard
deviation (SD) from at least three independent experiments.
The differences between groups were evaluated by means of a
Student’s t-test using SPSS 24.0, with p-values less than 0.05 being
considered indicative of statistical significance.
RESULTS
Clinical Findings in the Patient
The patient suffered from an attack of AP that appears to have
been triggered by the consumption of ∼150 g alcohol on October
29, 2017. On day 3 (October 31, 2017) of the disease onset, he
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was transferred from the local hospital to our therapy center at
Jinling Hospital, one of the biggest referral centers for severe
AP treatment in China. In our center, the patient was more
precisely diagnosed as having HTG-AP on the basis that his
TG level was as high as 17.8 mmol/L (Figure 1). Figure 2
shows computed tomography images of the affected pancreas
from two time points during the early days of the disease.
Continuous renal replacement therapy (CRRT) and pulmonary
ventilation were performed to rescue renal and respiratory
function, respectively. After a 64-day hospitalization in our
FIGURE 1 | Dynamic changes of the fasting plasma TG levels, post-heparin LPL mass and LPL activity during hospitalization and follow-up periods of the patient
with alcohol-triggered HTG-AP. Day 3 (D3), numbered by reference to the time of disease onset, corresponds to the date when the patient was transferred to our
service. See Table 1 for the precise values of the three parameters. HTG-AP, hypertriglyceridemia-induced acute pancreatitis; LPL, lipoprotein lipase; ICU, intensive
care unit.
TABLE 1 | Plasma lipid profiles and post-heparin LPL mass and activity in the patient.










LPL mass (% of
normal)†
LPL activity (% of
normal)‡
31 October 2017 Admission (D3)§ 9.3 17.80 13.69 2.87 9.21 ND ND
1 November 2017 D4 9.3 21.40 11.30 1.79 8.49 339.8 (182.3) 1.0445 (60.6)
2 November 2017 D5 10.2 6.39 5.32 1.27 3.09 429.0 (230.1) 1.1287 (65.5)
3 November 2017 D6 9.4 4.87 3.98 0.92 2.37 358.9 (192.5) 0.8841 (51.3)
5 November 2017 D8 9.1 2.23 3.34 0.38 1.43 395.6 (212.2) 1.0520 (61.0)
8 November 2017 D11 10.6 1.83 2.67 0.23 1.15 365.5 (196.1) 1.0881 (63.1)
15 November 2017 D18 8.1 1.93 2.47 0.26 1.71 219.2 (117.6) 1.1965 (69.4)
30 December 2017 D63 6.6 1.40 3.00 0.46 1.78 264.6 (141.9) 1.1939 (69.2)
2 January 2018 Switch to normal
ward
6.6 1.30 3.49 0.90 2.30 ND ND
7 February 2018 Discharge 5.6 1.08 4.58 1.10 3.00 ND ND
18 March 2018 Follow-up 6.07 1.46 5.51 1.2 3.19 ND ND
9 May 2018 Follow-up 4.95 1.55 5.22 1.23 3.28 ND ND
9 July 2018 Follow-up 4.07 1.32 4.43 1.00 2.8 ND ND
24 October 2018 Follow-up 4.32 1.35 3.8 1.13 2.23 ND ND
16 January 2019 Follow-up 5.22 1.25 4.71 1.38 2.75 ND ND
3 April 2019 Follow-up 4.93 1.63 5.45 1.52 3.13 213.9 (114.7) 1.2100 (70.2)
11 September 2019 Follow-up 4.64 1.44 4.95 1.33 2.84 ND ND
7 January 2020 Follow-up 5.02 1.70 5.04 1.19 3.37 ND ND
27 June 2020 Follow-up 4.70 1.76 5.31 1.44 3.14 ND ND
20 September 2020 Follow-up 4.97 1.94 5.28 1.35 3.39 ND ND
†Normal value (derived from eight healthy controls) was 186.4 ± 56.1 U/L.
‡Normal value (derived from eight healthy controls) was 1.7242 ± 0.4358 mEq/L/h.
§Admission to our service was on day 3 of disease onset. D, day; ICU, intensive care unit; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol;
LDL-C, low-density lipoprotein cholesterol; ND, not detected.
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FIGURE 2 | Abdominal computed tomography images of the patient showing the affected pancreas. The left image was taken on the third day of onset of acute
pancreatitis, showing peripancreatic exudation (arrow) and the enlarged pancreas with adjacent water density shadow. The right image was taken on the eighteenth
day of disease onset, showing the occurrence of infected pancreatic necrosis. The box indicates a partial necrotic pancreas whilst the arrows indicate infective
necrosis.
intensive care unit, and 40 days on a normal ward, he was
discharged on February 11, 2018.
Personal and Family History of the
Patient
The patient had an 8-year history of mild HTG (a fasting plasma
TG level of ∼5 mmol/L) and a 20-year history of continuous
consumption of ∼100 g alcohol per day. He had no prior attacks
of AP. He had had no cholelithiasis, diabetes or other diseases
that are known to cause HTG. He also had no history of drug
abuse. There was no family history of AP. His elder brother
was, however, reported to have drunk >80 g alcohol per day for
>20 years and had a borderline high TG (2.08 mmol/L).
Long-Term Measurement of TG Levels
and Post-heparin LPL Mass and Activity
in the Patient
Plasma lipid profiles and post-heparin LPL mass and activity
in the patient were determined regularly during his hospital
stay and follow-up period (Table 1 and Figure 1). The highest
LPL mass (429.0 U/L; ∼2.3 times higher than normal controls)
was observed on day 5 whereas the lowest LPL activity
(0.8841 mEq/L/h; ∼50% of normal controls) was observed on
day 6 of AP onset. It should be noted that during the follow-up
period, the patient abstained from both drinking and smoking
as advised; his TG levels remained at normal or at most
borderline high levels. The normal post-heparin LPL mass and
activity values were averages derived from eight healthy controls
(Table 1). Additionally, post-heparin LPL mass and activity in
the elder brother (187.6 U/L and 1.7112 mEq/L/h, respectively)
and son (274.3 U/L and 1.7338 mEq/L/h, respectively) were
found to be within the normal range (184.4 ± 56.1 U/L and
1.7242 ± 0.4358 mEq/L/h, respectively).
Genetic Findings in the Patient and His
Family Members
Sequencing of the LPL, APOA5, APOC2, LMF1, and GPIHBP1
genes in the patient led to the identification of two heterozygous
variants (Figure 3A). One was the common APOA5 c.553G > T
(p.Gly185Cys; rs2075291) variant, which has previously been
associated with altered TG levels (Kao et al., 2003; Tang et al.,
2006) as well as HTG-AP (Pu et al., 2020). The other is
a rare variant in the LPL gene, c.756T > G (p.Ile252Met).
This latter variant has an allele frequency of 0.000003978
(1/251358) in the gnomAD dataset (see text footnote 1).
It does not, however, appear in the literature nor has it
been registered in HGMD (see text footnote 2), ClinVar (see
text footnote 3) or the LPL locus-specific mutation database
(see text footnote 4) (as of 22 September 2020). The LPL
p.Ile252 position is strictly conserved during mammalian and
avian evolution (Figure 3C) and the p.Ile252 variant was
predicted to be “pathogenic” in accordance with the PP3 rule
established by VarSome (Kopanos et al., 2019). This pathogenicity
assessment was based on nine independent predictions from
BayesDel_addAF, DANN, DEOGEN2, FATHMM-MKL, M-CAP,
MutationAssessor, MutationTaster, REVEL, and SIFT against 3
benign predictions from EIGEN, MVP, and PrimateAI.
The patient’s older brother, wife and son were also available
for genetic analysis. The brother and son were found to carry the
common APOA5 p.Gly185Cys variant (Figure 3B).
Frontiers in Genetics | www.frontiersin.org 5 April 2021 | Volume 12 | Article 640859
fgene-12-640859 May 6, 2021 Time: 10:44 # 6
Yang et al. Novel Digenic Mutation in HTG-AP
FIGURE 3 | Genetic variants detected in the patient and the family tree.
(A) Sanger sequencing electropherogram showing the novel LPL c.756T > G
(p.Ile252Met) variant and the known common APOA5 c.553G > T
(p.Glu185Cys) variant identified in the patient. The variants are indicated by
arrows. (B) Arrow denotes the patient. Genotype status with respect to the
APOA5 c.553G > T and LPL c.756T > G variants, age, BMI and TG levels are
provided for each subject. (C) Alignment of partial LPL amino acid sequences
spanning the p.252 site. LPL, lipoprotein lipase; APOA5, apolipoprotein A5;
BMI, body mass index; het, heterozygous; wt, wild-type; TG, triglyceride; NA,
not analyzed.
In vitro Functional Characterization of
the LPL p.Ile252Met Missense Variant
We firstly performed Western blot analysis of LPL expressed in
the transfected cells without heparin treatment. No difference
was found between the wild-type, wild-type/mutant, and mutant
expression vector groups (Figure 4). We then performed western
blot analysis of LPL present in the transfected cell lysates and
those secreted into the culture medium after heparin treatment
(exogenous heparin promotes the release of cell surface-bound
LPL into the medium). No difference was found between the
three groups in either case (Figure 5). However, the mutant
expression vector yielded reduced LPL activity in both cell
lysates and medium. More specifically, the reduction from
the “homozygous” mutant expression vector was approximately
double that from the “heterozygous” mutant expression vector
and, if expressed in the context of alleles, we estimate that the
mutation caused a 40% loss of enzyme activity as compared to the
wild-type (Figure 6). Taken together, the LPL p.Ile252Met variant
served to reduce the enzymatic activity of the LPL protein but did
not exert a dominant-negative effect.
DISCUSSION
In the present study, we report the detailed clinical, biochemical
and family analysis of a patient with alcohol-triggered HTG-
AP as well as the in vitro functional analysis of the rare LPL
p.Ile252Met variant. We obtained long-term data on TG levels
and post-heparin LPL mass and activity for the patient and
performed in vitro functional analysis of the missense variant
of interest in both the “heterozygous” and “homozygous” state
and under different experimental conditions (with and without
heparin treatment). Integration of these findings provides
several novel insights into the complex etiology of HTG
and HTG-AP.
First, the patient was found to carry a known common
risk single nucleotide polymorphism (SNP) (i.e., APOA5
c.553G > T (p.Gly185Cys); rs2075291) and a rare variant [i.e.,
LPL c.756T > G (p.Ile252Met)]. APOA5 c.553G > T has
an allele frequency of 0.06765 in East Asians (according to
gnomAD); and in the Asian population, c.553T carriers displayed
an increased risk of HTG as compared with c.553 GG carriers,
with the overall random effects odds ratio (OR) being 3.55
[95% confidence interval (CI) 2.46 to 5.13] in the context of
a dominant genetic model (He et al., 2016). By reference to
the definitions employed by Manolio et al. (2009), the APOA5
c.553G > T variant may be best described as a common genetic
variant with moderate genetic effect (on HTG) in the Asian
population. By contrast, the LPL c.756T > G (p.Ile252Met)
variant is extremely rare in normal populations (allele frequency
of 0.000003978 according to gnomAD) and has not previously
been reported in HTG patients. The p.Ile252 site is conserved
across the classes Mammalia and Aves (Figure 3C), suggesting
its functional importance for protein structure and function.
Consistent with the conservation of Ile252 over 300 million years
of evolution, p.Ile252Met was predicted to be pathogenic by 9
of the 13 in silico algorithms employed by VarSome (Kopanos
et al., 2019). Further, post-heparin LPL activity in the patient
is approximately 70% of normal (Table 1 and Figure 1). It
should be noted here that the post-heparin LPL activity in
the patient was, in fact, a reflection of the net result of the
complex interaction between the LPL gene and its regulating
genes (such as APOC2, APOA5, GPIHBP1, and LMF1) as well
as environmental and lifestyle factors. Thus, to decipher the
direct effect of the p.Ile252Met variant on LPL protein and
function, we further performed an in vitro transfection study,
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FIGURE 4 | Western blot analysis of LPL expression in transfected HEK293T cells without heparin treatment. (A) Results were the average taken from three
independent experiments. (B) LPL, lipoprotein lipase; WT, wild-type; EV, empty vector.
which demonstrated that the mutant p.Ile252Met allele caused
a 40% loss of enzyme activity as compared to the wild-type
allele (Figure 6). Based upon these observations, we believe
that it is reasonable to define the LPL p.Ile252Met variant as
a rare genetic variant that confers a rather moderate effect on
LPL function (and presumably on HTG). Taken together, the
patient was determined to have a digenic basis for his previous
mild HTG and the current severe HTG-AP. To the best of our
knowledge, this is the first time that trans heterozygosity for
a common variant and a rare variant, both of which have a
moderate effect on HTG, has been described in this disease.
In this regard, it is pertinent to mention that in the context
of TG-related genes, common variants are generally thought to
have a small genetic effect whereas rare variants are thought to
have a strong genetic effect (Johansen and Hegele, 2011; Dron
and Hegele, 2020). Additionally, it should also be appreciated
that the APOA5 p.Gly185Cys variant appeared to amplify the
effect of the LPL p.Ile252Met variant on reducing LPL activity,
as the reduction of the plasma LPL activity in the patient (30%
lower than normal) was 10% higher than the reduction of the
LPL activity conferred by the “heterozygous” mutant LPL variant
in vitro (20% lower than wild-type). Although care should always
be exercised when comparing in vivo data directly with in vitro
data, such a difference has a strong biological basis. The APOA5
p.Gly185Cys impairs the function of APOA5; since APOA5 is
an activator of LPL, this loss-of-function leads in turn to less
activated LPL (Dorfmeister et al., 2008; Huang et al., 2012;
Sharma et al., 2014; Chang et al., 2018).
Second, alcohol abuse is the most important environmental
factor causing HTG owing to its impact on very-low-density
lipoprotein secretion, lipolysis and free fatty acid fluxes from
adipose tissue to the liver (Van de Wiel, 2012; Klop et al., 2013;
Zemánková et al., 2015). Herein, having performed long-term
follow-up of the TG levels in the patient, we were able to report
a previously undescribed scenario: whereby the consumption of
150 g alcohol apparently triggered the attack of severe HTG-AP,
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FIGURE 5 | Western blot analysis of post-heparin LPL expression in cell lysates (A) and media (B) of transfected HEK293T cells. Results were the average taken
from three independent experiments. LPL, lipoprotein lipase; WT, wild-type; EV, empty vector.
FIGURE 6 | Post-heparin LPL activity in transfected HER293T cell lysates (A) and medium (B). Results were expressed as mean ± SD from three independent
transfections, with each transfection being performed in five replicates. LPL, lipoprotein lipase; WT, wild-type; EV, empty vector. *p < 0.05; **p < 0.01; ***p < 0.001.
the daily consumption of ∼100 g alcohol over 20 y is likely to have
contributed to his pre-existing mild-HTG. This latter postulate
was based on the observation that the TG levels in the patient
remained normal, or at most borderline high, during the nearly
3-year follow-up period, during which the patient had completely
abstained from drinking alcohol. Further follow-up studies are,
however, needed to draw a firm conclusion.
Third, most of the HTG-associated rare LPL missense variants
reported to date result in a complete or >90% functional loss
of the affected allele, with this functional loss often being linked
to upstream effects on protein synthesis, transport and secretion
rather than to an isolated effect on enzyme activity (Rouis et al.,
1996; Murano et al., 2005; Yu et al., 2006; Liu et al., 2016; Shi
et al., 2020). To date, we are aware of only one rare LPL missense
variant in the literature (i.e., a homozygous p.Ala203Thr variant
found in a LPL-deficient patient) that specifically disrupted
enzyme activity (Beg et al., 1990). However, both in vivo and
in vitro findings (Beg et al., 1990) pointed to the p.Ala203Thr
variant experiencing a complete loss of enzymatic activity. By
contrast, the LPL p.Ile252Met mutant currently described here
retained 60% enzyme activity as compared to its wild-type
counterpart. Interestingly, p.Ile252Met occurred within a region
of LPL, encompassing amino acid positions 243 to 266, that
plays a crucial role in determining lipase substrate specificity
(Dugi et al., 1995).
Lastly, we observed that whereas LPL mass was significantly
increased in the patient during the acute phase of HTG-AP,
LPL activity remained essentially unchanged at 70% normal
(Figure 1). We surmised that this may be due to a dominant-
negative effect of the mutant LPL p.Ile252Met allele, given that
LPL is active mainly as a homodimer (Griffon et al., 2009; Arora
et al., 2019; Beigneux et al., 2019). To explore this postulate,
we mimicked the heterozygous state of the variant by mixing
an equal amount of wild-type and mutant expression vectors
in the transfection experiments. As shown in Figure 6, the
impact of the “homozygous” variant was approximately double
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that of the “heterozygous” variant in terms of reducing LPL
activity, thereby excluding such a postulate. It might also be
that under stress of severe HTG, a positive feedback cycle
stimulated LPL synthesis. However, a significant fraction of
rapidly synthesized LPL proteins may not fold correctly and
hence might not function normally. In this regard, it did not
escape our attention that in the aforementioned LPL-deficient
patient carrying the LPL p.Ala203Thr variant, higher than normal
LPL mass concentrations were present in both pre- and post-
heparin samples (Beg et al., 1990). It should, however, be noted
that no information was available as to whether or not the
patient had AP when the analysis was performed. Moreover,
unlike our patient who had retained 70% normal LPL activity,
the homozygous p.Ala203Thr carrier had no LPL activity at all.
Consequently, we surmise that in this latter patient, the increased
LPL mass may more likely be due to a feedback stimulus resulting
from the absence of LPL activity. Irrespective of the underlying
reasons, the increased LPL mass in both patients is consistent
with the in vitro evidence that the respective LPL missense
variants did not affect either protein synthesis or secretion.
The above notwithstanding, it should be emphasized that this
study focused on a single case with HTG-AP. Further studies of
more cases are required for us to obtain a better understanding
of the genotype-phenotype relationships underlying this rare
entity. Moreover, although loss-of-function APOA5 variants have
previously been shown to lead to less activated LPL by several
studies (Dorfmeister et al., 2008; Huang et al., 2012; Sharma
et al., 2014; Chang et al., 2018), co-transfection experiments of
APOA5 p.Gly185Cys and LPL p.Ile252Met expression vectors
would be expected to yield confirmatory evidence for the gene-
gene interaction between the two variants.
CONCLUSION
We provide concrete evidence that gene-gene and gene-
environment interactions are responsible for causing mild HTG
and HTG-AP in this patient. The novel insights generated from
this study not only improve our understanding of the complex
etiology of HTG, but also have important implications for variant
interpretation as well as disease prevention. For example, the
study of the novel LPL p.Ile252Met variant clearly demonstrates
that rare variants can confer a small or modest effect in the same
way as common variants. Moreover, whereas the evaluation of
evolutionary conservation and in silico pathogenicity prediction
are both helpful in assessing the pathogenic relevance of
missense variants, the precise underlying biological mechanisms
can only be addressed by in vitro functional analysis. Finally,
subjects found to carry any genetic risk factors for HTG
should be well advised to be abstemious with regard to their
alcohol consumption.
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